Previous 10 | Next 10 |
ContraFect ( CFRX ) -19% . United Maritime ( USEA ) -14% . Organovo Holdings ( ONVO ) -9% . Revelation Biosciences ( REVB ) -9% . Melco Resorts & Entertainment ( MLCO ) -7% after Chinese regulators close Macau casinos to cu...
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...
Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%. Neptune Wellness Solutions (NEPT) -19%. Sc...
One of the best parts about penny stocks is that there are so many of them right now. Similar to what we saw during the pandemic, hundreds of companies had fallen victim to the broad sector sell-offs this year. It hasn’t only been “start-ups” either. Plenty of househo...
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compou...
YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Ve...
YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal...
Contrafect press release (NASDAQ:CFRX): Q1 GAAP EPS of -$0.51. Cash and cash equivalents of $9.6M For further details see: Contrafect GAAP EPS of -$0.51
YONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023